This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: July 17, 2007
Last updated: November 30, 2010
Last verified: November 2010
To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

Bronchial Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database

Further study details as provided by AstraZeneca:

Enrollment: 1000
Study Start Date: June 2007
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Population comes from Primary Care Clinics and Pulmonary Experts

Inclusion Criteria:

  • Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00503061

United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Principal Investigator: Catriona McMahon, MD AZ UK MC
Study Director: Tomas Andersson, MD AZ R&D Lund
  More Information

Additional Information:
Responsible Party: Tomas Andersson, MSD, AstraZeneca Pharmaceuticals Identifier: NCT00503061     History of Changes
Other Study ID Numbers: D5890C00017
Study First Received: July 17, 2007
Last Updated: November 30, 2010

Keywords provided by AstraZeneca:
Symbicort SMART

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents processed this record on August 16, 2017